Aelis Farma SA

Paris Stock Exchange AELIS.PA

Aelis Farma SA Interest Coverage Ratio for the year ending December 31, 2023: -30.92

Aelis Farma SA Interest Coverage Ratio is -30.92 for the year ending December 31, 2023, a 78.75% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.
  • Aelis Farma SA Interest Coverage Ratio for the year ending December 31, 2022 was -145.51, a -2,618.08% change year over year.
  • Aelis Farma SA Interest Coverage Ratio for the year ending December 31, 2021 was 5.78, a 122.18% change year over year.
  • Aelis Farma SA Interest Coverage Ratio for the year ending December 31, 2020 was -26.06, a 40.28% change year over year.
  • Aelis Farma SA Interest Coverage Ratio for the year ending December 31, 2019 was -43.63, a 22.72% change year over year.
Key data
Date Interest Coverage Ratio Debt to Equity Ratio Interest Expense To Sales Inventory Turnover Ratio
Market news
Paris Stock Exchange: AELIS.PA

Aelis Farma SA

CEO Dr. Pier Vincenzo Piazza M.D., Ph.D.
IPO Date Feb. 18, 2022
Location France
Headquarters 146 rue Léo Saignat
Employees 26
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Aelis Farma SA, a biotechnology company, engages in the research and development of treatments for brain diseases. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which completed Phase 1 clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is based in Bordeaux, France.

StockViz Staff

January 15, 2025

Any question? Send us an email